Glucose uptake assay (Fluorometric, Direct Glucose) (ab234043)
Key features and details
- Assay type: Cell-based (quantitative)
- Detection method: Fluorescent
- Platform: Microplate reader
- Sample type: Adherent cells, Suspension cells
Overview
-
Product name
Glucose uptake assay (Fluorometric, Direct Glucose)
See all Glucose uptake kits -
Detection method
Fluorescent -
Sample type
Adherent cells, Suspension cells -
Assay type
Cell-based (quantitative) -
Product overview
Glucose uptake assay (Fluorometric, Direct Glucose) (ab234043) follows a simple and ultra-sensitive protocol to detect glucose uptake in various cells.
A specific hexokinase inhibitor that inhibits hexokinase, the first enzyme metabolizing glucose in cells is used to arrest glucose consumption after its uptake. Glucose Uptake is measured by using a set of enzymatic reactions that specifically oxidize glucose producing intermediates that react with the Glucose Red Probe generating a fluorescence signal (Ex/Em=535/587 nm). The fluorescence signal is directly proportional to the amount of glucose that has been taken up and accumulated inside the cells. Unlike other kits detecting glucose derivatives, this glucose uptake assay provides a direct, powerful tool for studying this process as well as for screening and characterization of drugs that regulate glucose uptake during normal and disease development.
-
Notes
Glucose uptake is one of the key processes for cellular glucose metabolism. The study of glucose uptake can provide important information for understanding glucose metabolism and regulation in normal and disease development such as diabetes
-
Platform
Microplate reader
Properties
-
Storage instructions
Store at -20°C. Please refer to protocols. -
Components 50 tests Assay Buffer 1 x 25ml Enzyme Mix 1 vial Glucose (1 M, Sterile) 1 x 1ml Glucose Red Probe 1 x 200µl Glucose Standard (100 mM) 1 x 100µl Hexokinase Inhibitor 1 vial
Images
-
Glucose standard curve.
Data provided for demonstration purposes only.
-
Jurkat (Human T cell leukemia cell line from peripheral blood) cells were starved (glucose-free, FBS-free medium). Inhibitor incubation time, 2 hours.
-
NIH/3T3 (Mouse embryo fibroblast cell line) cells were starved (glucose-free and FBS-free) for 24 hours then switched to glucose-containing medium and treated +/- insulin (10 ng/ ml) for 15 minutes in the presence or absence of Hexokinase Inhibitor.
-
HeLa (Human epithelial cell line from cervix adenocarcinoma) cells were starved for 2 hours (glucose-free and FBS-free media) then switched to either glucose- and FBS-free medium or complete (with 10% FBS) medium with or without Hexokinase Inhibitor for 30 minutes.